Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Phase

Division (Location)

Study ID

NCT#

Brief Description
Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.